These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review. Wong S; Kwan ATH; Teopiz KM; Le GH; Meshkat S; Ho R; d'Andrea G; Cao B; Di Vincenzo JD; Rosenblat JD; McIntyre RS J Affect Disord; 2024 Apr; 350():698-705. PubMed ID: 38244804 [TBL] [Abstract][Full Text] [Related]
10. Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023. Havlik JL; Wahid S; Teopiz KM; McIntyre RS; Krystal JH; Rhee TG Curr Psychiatry Rep; 2024 Apr; 26(4):176-213. PubMed ID: 38386251 [TBL] [Abstract][Full Text] [Related]
11. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. McIntyre RS; Filteau MJ; Martin L; Patry S; Carvalho A; Cha DS; Barakat M; Miguelez M J Affect Disord; 2014 Mar; 156():1-7. PubMed ID: 24314926 [TBL] [Abstract][Full Text] [Related]
12. Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine. Garakani A J Psychiatr Pract; 2021 Nov; 27(6):496-497. PubMed ID: 34768276 [TBL] [Abstract][Full Text] [Related]
13. Role of Ketamine in the Treatment of Psychiatric Disorders. Derakhshanian S; Zhou M; Rath A; Barlow R; Bertrand S; DeGraw C; Lee C; Hasoon J; Kaye AD Health Psychol Res; 2021; 9(1):25091. PubMed ID: 35106397 [TBL] [Abstract][Full Text] [Related]
14. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States. Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167 [TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
16. Repetitive Transcranial Magnetic Stimulation for People With Treatment-Resistant Depression: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2021; 21(4):1-232. PubMed ID: 34055112 [TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy for Treatment-Resistant Depression: Antidepressants and Atypical Antipsychotics. Vas C; Jain A; Trivedi M; Jha MK; Mathew SJ Psychiatr Clin North Am; 2023 Jun; 46(2):261-275. PubMed ID: 37149344 [TBL] [Abstract][Full Text] [Related]
18. Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review. Caldiroli A; Capuzzi E; Tagliabue I; Capellazzi M; Marcatili M; Mucci F; Colmegna F; Clerici M; Buoli M; Dakanalis A Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884874 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study. Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752 [TBL] [Abstract][Full Text] [Related]
20. Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review. Di Vincenzo M; Martiadis V; Della Rocca B; Arsenio E; D'Arpa A; Volpicelli A; Luciano M; Sampogna G; Fiorillo A Front Psychiatry; 2024; 15():1394787. PubMed ID: 38812489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]